Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial

Lancet

Volumn 364, Issue 9431, 2004, Pages 331-337

  Diener, Prof Hans Christoph ^a   Bogousslavsky, Prof Julien ^b   Brass, Prof Lawrence M ^c   Cimminiello, Prof Claudio ^d   Csiba, Prof Laszlo ^e   Kaste, Prof Markku ^f   Leys, Prof Didier ^g   Matias Guiu, Prof Jordi ^h   Rupprecht, Prof Hans Jürgen ⁱ  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DESIO HOSPITAL   (Italy)

^e UNIVERSITY OF DEBRECEN   (Hungary)

^f UNIVERSITY OF HELSINKI   (Finland)

^g UNIV LILLE   (France)

^h HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

ⁱ JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PLACEBO;

ADULT; AGED; ANALYTIC METHOD; ANGINA PECTORIS; ARTERY DISEASE; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG SCREENING; FEMALE; FOLLOW UP; HEART INFARCTION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONBIOLOGICAL MODEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECORDING; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TRANSIENT ISCHEMIC ATTACK;

AGED; ASPIRIN; CEREBROVASCULAR ACCIDENT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMORRHAGE; HUMANS; INTRACRANIAL HEMORRHAGES; ISCHEMIC ATTACK, TRANSIENT; MALE; PLATELET AGGREGATION INHIBITORS; RECURRENCE; RISK FACTORS; TICLOPIDINE;

EID: 3242770664     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)16721-4     Document Type: Article

References (21)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 524: 71-86.
2. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
3. Ringleb P, Bhatt D, Hirsch A, Topol E, Hacke W, on behalf of the CAPRIE Investigators. The benefit of clopidogrel over aspirin is amplified in patients with a prior history of ischemic events. Stroke 2004; 35: 528-532.
4. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol. 90:2002;625-628
5. Bhatt DL, Chew DP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation. 103:2001;363-368
6. Bhatt D, Foody J, Hirsch A, Ringleb P, Hacke W, Topol E. Complementary, additive benefit of clopidogrel and lipid-lowering therapy in patients with atherothrombosis. J Am Coll Cardiol. 35:(suppl A):2000;326
7. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
8. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 288:2002;2411-2420
9. Diener HC, Bogousslavsky J, Brass LM, et al. Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data. Cerebrovasc Dis. 17:2004;253-261
10. Adams HP Jr, Bendixen BH, Kappelle JL, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. Stroke. 24:1993;35-41
11. Robert A. Cytoprotection by prostaglandins. Gastroenterology. 77:1979;761-767
12. Fork FT, Lafolie P, Tóth E, Lindgärde F. Gastroduodenal tolerance of 75 mg clopidogrel versus 325 mg aspirin in healthy volunteers. Scand J Gastroenterol. 35:2000;464-469
13. García Rodríguez LA, Hernández-Díaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiological studies. Br J Clin Pharmacol. 52:2001;563-571
14. Stalnikowicz-Darvasi R. Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis. J Clin Gastroenterol. 21:1995;13-16
15. Slattery J, Warlow CP, Shorrock CJ, Langman MJ. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin: analysis of gastrointestinal bleeding during the UK-TIA trial. Gut. 37:1995;509-511
16. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 310:1995;827-830
17. Harker LA, Boissel J-P, Pilgrim AJ, Gent M, on behalf of the CAPRIE Steering Committee and Investigators. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. Drug Safety 1999; 21: 325-335.
18. Topol EJ, Easton JD, Harrington RA, et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation. 108:2003;16-23
19. Algra A, van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry. 66:1999;255
20. Sacco M, Pellegrini F, Roncaglioni MC, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care. 26:2003;3264-3272
21. Hankey GJ. Ongoing and planned trials of antiplatelet therapy in the acute and long-term management of patients with ischaemic brain syndromes: setting a new standard of care. Cerebrovasc Dis. 17:(suppl 3):2004;11-16